Bristol-Myers Squibb Co (BMY) Holdings Trimmed by Gabelli Funds LLC

Gabelli Funds LLC decreased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 0.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 721,787 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. Gabelli Funds LLC’s holdings in Bristol-Myers Squibb were worth $37,518,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Arlington Partners LLC increased its stake in shares of Bristol-Myers Squibb by 40.0% during the fourth quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 400 shares in the last quarter. CKW Financial Group boosted its position in Bristol-Myers Squibb by 29.4% during the fourth quarter. CKW Financial Group now owns 2,200 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 500 shares during the last quarter. Cypress Capital Management LLC WY boosted its position in Bristol-Myers Squibb by 154.7% during the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 1,160 shares during the last quarter. NuWave Investment Management LLC boosted its position in Bristol-Myers Squibb by 5,418.2% during the fourth quarter. NuWave Investment Management LLC now owns 2,428 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 2,384 shares during the last quarter. Finally, Lavaca Capital LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth about $127,000. 73.19% of the stock is owned by institutional investors.

NYSE:BMY opened at $50.22 on Monday. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $81.97 billion, a price-to-earnings ratio of 12.62, a PEG ratio of 1.60 and a beta of 0.83. Bristol-Myers Squibb Co has a 1-year low of $44.30 and a 1-year high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 50.03%. Bristol-Myers Squibb’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.68 EPS. Equities analysts expect that Bristol-Myers Squibb Co will post 4.16 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, February 1st. Shareholders of record on Friday, January 4th were issued a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.27%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend was Thursday, January 3rd. Bristol-Myers Squibb’s payout ratio is presently 41.21%.

A number of research firms recently weighed in on BMY. Credit Suisse Group set a $61.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Sunday, October 14th. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, October 22nd. Citigroup lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $62.00 to $57.00 in a research report on Monday, October 22nd. ValuEngine lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Finally, BMO Capital Markets boosted their price target on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a “market perform” rating in a research report on Friday, November 16th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and seven have issued a buy rating to the company. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $60.21.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Holdings Trimmed by Gabelli Funds LLC” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2019/02/11/bristol-myers-squibb-co-bmy-holdings-trimmed-by-gabelli-funds-llc.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Recommended Story: Stock Split

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply